In this exclusive interview, the Bioptimus CEO explains why AI‑powered foundation models are becoming the operating system of drug discovery, how they move from prediction to mechanistic understanding and why strategic partnerships are critical for pharma leaders. Discover insights on scaling laws, ethics, and talent strategies shaping the next era of biopharma innovation.
Topics:
- Foundation Models in Biology
- Data Quality & Interoperability
- From Prediction to Understanding
- Scaling Laws in Biology
- AI as a Strategic Asset
- Regulation & Trustworthiness
- Public-Private Partnerships
- Ethical Use of Biological Data
- Talent & Organizational Change
- The Future of BiAI Startups